

Klaus F. Rabe MD, PhD

Christian Albrecht University Kiel & LungenClinic Grosshansdorf

(MEMBERS OF THE GERMAN CENTER FOR LUNG RESEARCH)







#### World Conference on Research Integrity, Rio de Janeiro 2015



## Measuring Success Within the German Center for Lung Research Implications for Research Integrity

#### Conflict of Interest Klaus F. Rabe:

I am a director of the German Center for Lung Research (DZL), a position which is not renumerated. My travel to this meeting is funded by DZL.

My institution receives federal funding for the research activities of the DZL

I have been involved in drug development and have spoken in educational events and witnessed for the pharmaceutical industry in front of EMA and FDA

I hold no shares or have any proprietory interest in any pharmaceutical company

I have never worked with the tobacco industry (and never will)

#### The German Centers for Health Research





Federal Government in Germany Resolution

"Health Research Framework Program"

6 German Centers of Health Research form the core of the program 200 Mio € p. a. for the Centers, funded by the Federal Ministry for Education and Research (BMBF) (90%) and the host States (10%)

Long term "institutions" envisioned

2009 German Center for Diabetes Research (DZD)

German Center for Neurodegenerative Diseases (DZNE)

2011 German Center for Cardiovascular Research (DZHK)

German Center for Infection Research (DZIF)

German Consortium for Translational Cancer Research (DKTK)

German Center for Lung Research (DZL)





#### German Centers of Health Research

- Deutsches Zentrum f
   ür
   Herz-Kreislauf-Forschung (DZHK)
- Deutsches Zentrum für Infektionsforschung (DZIF)
- Deutsches Zentrum für Lungenforschung (DZL)
- Deutsches Konsortium f
  ür Translationale Krebsforschung (DKTK)
- Deutsches Zentrum f
  ür Diabetesforschung (DZD)
- Deutsches Zentrum für Neurodegenerative Erkrankungen (DZNE)



#### **DZL** Organization



- 5 Coordinating Centers
- 22 Research Institutions
  - Universities with hospitals
  - Top non-academic research institutions
- > 200 affiliated Principal Investigators
- Coordinated by Central Office in Giessen
- Oversight Bodies
  - International Scientific Advisory Board
  - General Assembly
  - Commission of Funding Authorities



# Mission Statement of the DZL



Translational Research

to Combat Widespread

Lung Diseases





### **DZL Scientific Advisory Board**



- Peter J Barnes, Imperial College London, UK
- Rachel Chambers, University College London, UK
- Jeffrey Drazen, Harvard Medical School, Boston, USA
- Stuart Elborn, Queens University Belfast, UK
- Mark Gladwin, University of Pittsburgh Medical Center, USA

- Marlene Rabinovitch, Stanford University, Palo Alto, USA
- Susan Shurin, National Institutes of Health, Bethesda, USA
- Peter Suter, University of Geneva, Switzerland
- Jacob Sznajder, Northwestern
  University Feinberg School of
  Medicine, Chicago, USA


### Disease Areas in Focus of the DZL



- Asthma and Allergy (AA)
- Chronic Obstructive Lung Disease/Emphysema (COPD)
- Cystic Fibrosis (CF)
- Pneumonia and Acute Lung Injury (ALI)
- Diffuse Parenchymal Lung Disease (DPLD)
- Pulmonary Hypertension (PH)
- End-stage Lung Disease (ELD)
- Lung Cancer (LC)

### **Unifying Scientific Concept**






 Harnessing for anti-inflammatory, anti-obstructive and resolution promoting therapy and tissue repair Identification of targets for innovative therapies

#### **Concerted Translational Strategy**





03.02.2023



#### **Commitment to Infrastructure**

- Biobank
- Imaging Platform
- Unified Data Management Platform
- DZL Technology Transfer Consortium

#### **Commitment to Training and Outreach**


- International Lung School (Germany-France)
- DZL Mentoring Program
- Lung Information Service

#### **Core Facilities At Various DZL Sites**



- Genetics
- Transcriptomics/Epigenetics/microRNA
- Lipidomics/Metabolomics/Proteomics
- Microbiome
- Bioinfomatics, Systems Biology
- Phase I/IIa Trial Centre
- GLP Animal Facility
- Lung Stem Cell and Transfection Unit
- Aerosol Technology and inhalation chambers
- Systems Medicine
- Animal Models in all Disease Areas





**Synergies With Other German Health Centers** 

Common Mission Statement

Translational research to combat widespread lung diseases

Complementary Disease focus

Airway – Lung Parenchyma – Vasculature Pediatric – Adult

Complementary Expertise

Basic Science – Disease-orientated- Patient-orientated-Epidemiological Research

Complementary Institutional Background

Helmholtz – Max Planck – Leibniz – Fraunhofer – University Hospitals – Pneumology Centers

Bundling of Resources

Knowledge – Technologies – Biobanks – Patient cohorts

Synergies in Technologies

Molecular Tools – Animal Models – Imaging & Biobank – Clinical Trials & Epidemiology

Synergies in Budgetary Focus

Investment in shared technologies – Coherent development strategy

Incentives for Cooperation

Largely cooperative disease programs – Clinical trial funds – Exchange programs





#### Correspondence

www.thelancet.com/respiratory Vol 2 August 2014

 Research outcome measures include the number of new experimental models established, targets and biomarkers identified or introduced into clinical studies, and therapies or diagnostic procedures entered into clinical practice

### Correspondence

www.thelancet.com/respiratory Vol 2 August 2014

 Clinical programmes include initiation of and participation in clinical studies by the organisation's faculty, and new registries or clinical cohorts

#### Correspondence

www.thelancet.com/respiratory Vol 2 August 2014

 Development, maintenance, and use of a common infrastructure, which otherwise might not exist, is a key indicator of the value added through creation of a large translational research programme (eg, biomaterial repositories, image databases, and unified data management structures)

### Correspondence

www.thelancet.com/respiratory Vol 2 August 2014

 Output measures include the number and effectiveness of publications in the field, H index of faculty, number of patents filed, third party funding, and evidence of increased collaboration as measured by shared authorship across partners and centres

#### Correspondence

www.thelancet.com/respiratory Vol 2 August 2014

Networking, training, and outreach were emphasised by the US Institute of Medicine as core elements of the Clinical and Translational Science Award programme, which is in line with the DZL view; these measures include initiation of and participation in national and international research consortia, implementation of programme-wide training, mentoring and clinician-scientist career programmes, workshops and symposia for the scientific community or general public, and web-based educational initiatives

#### **DZL International Symposia**



Year	Location	Conference Title
2012	Marburg UGMLC	Remodeling, Repair and Regeneration in Lung Diseases
2013	Munich CPC-M	Lung Aging: Molecular Mechanisms and Clinical Relevance
2014	Hannover BREATH	Lung Regeneration and Beyond: BREATH meetings REBIRTH



Munich Lung
Conference 2013
International
DZL Symposium

Lung Aging: Molecular
Mechanisms and Clinical
Relevance
October 4 - 5, 2013
Munich, Germany



#### Save the Date!





## Frontiers in Chronic and Malignant Airway Disease

June 25 – 27, 2015

Kongresshaus Stadthalle Heidelberg, Germany







- About the DZL
- •Centers
- Research
- Announcements
- News and Events

#### The German Center for Lung Research

The German Center for Lung Research (DZL) is an association of the leading university and non-university institutions dedicated to lung research in Germany. Using translational research methods, the DZL seeks to jointly develop new approaches for the prevention, diagnosis and therapy of serious lung diseases including asthma, chronic obstructive pulmonary disease (COPD), cystic fibrosis, diffuse parenchymal lung disease (DPLD), endstage lung disease, lung cancer, pneumonia and acute lung injury, and pulmonary hypertension.

#### Record attendance at the 11th Patient Forum "COPD" at DZL site Grosshansdorf

More than 150 participants attended the patient forum of the "Lung Information Service" and the "LungenClinic Grosshansdorf"... Read more...

DZL Scientists honored at 56th DGP Congress in Berlin, German Federal Health Minister praised DZL and LIS

#### Read more...

Experts recommend screening programs for people at high risk for lung cancer

DZL investigator Prof. Hans-Ulrich Kauzcor first author of accompanying publication with recommendations for the policy

New in PubMed

**New This Week From DZL Faculty** 

International Symposis

Click here for details about the 4th DZL International Symposium, including online registration and abstract submission.

**Upcoming Events** 

25.06.2015

2015 TLRC Lung Conference, 4th DZL International Symposium, "Frontiers in Chronic and Malignant Airway Disease"

16.08.2015 - 22.08.2015

Gordon Research Conference on Lung Development, Injury and Repair

26.09.2015 - 30.09.2015

ERS Annual Congress - 2015

31.01.2016 - 03.02.2016


5th DZL Annual Meeting in Hannover

14.04.2016 - 16.04.2016

**ERS Course: Interstitial Lung Diseases** 









- There is an urgent need for rules, standards of conduct (DFG)
- These rules needs to be formalised (contract)
- Awareness and education (!)
- Leading by example and trusting each other
- Benefitting the community and the network
- Large networks are extremely prolific and should allow for generosity